PRESS RELEASES | ENGLISH
Mentice exercise of over-allotment option and end of stabilisation period
DOCUMENTS | ENGLISH
PRESSMEDDELANDEN | SVENSKA
Mentice avser att notera bolagets aktier på Nasdaq First North Premier
Mentice utnyttjande av övertilldelningsoption och avslutande av stabiliseringsperiod
DOKUMENT | SVENSKA
Mentice Prospekt 2019 | Inbjudan till förvärv av aktier
Anmälningssedel för teckning av aktier i Mentice AB
Teoretisk Nettoskuldsättning Efter Erbjudandet
IMPORTANT DATES
Application period for the general public | 5-13 June 2019 |
Application period for insitutional investors | 5-14 June 2019 |
First day of trading on Nasdaq First North Premier | 18 June 2019 |
Settlement day | 19 June 2019 |
Mentice is a company that offers highly technological solutions for simulation to the medical sector with a focus on the fast-growing market for endovascular procedures. Mentice's simulators are used to educate, train, and improve surgeons' skills in various types of procedures and when introduced to new clinical instruments. Mentice was founded in 1999 and has since then developed a wide product portfolio with a majority of the largest medical technology companies as clients. Mentice's simulators have been installed in approximately 400 hospitals and academic institutions around the world and over 1,250 simulation systems have been delivered to hospitals and medical devices manufacturers.
“One of the major factors driving Mentice growth is the rapid, general transition from open surgery to minimally invasive procedures and, of particular importance for Mentice, image-guided endovascular treatments. As an example of this transition, a study was published in the USA during the first quarter of the year which discussed experiences from aortic valve operations. Transcatheter aortic valve replacement or implantation (TAVR/TAVI) will undoubtedly become the predominant technique in the future and its was said that there is little or no reason to perform open surgery for this treatment any longer. This is one of the many areas that will drive our growth.”
Göran Malmberg, Group CEO & President Mentice
BUSINESS IDEA
Mentice’s business idea is to assist in the aim to reduce deaths, injuries and costs resulting from medical errors and inefficiencies and ultimately reduce risk for harm to patients. By developing and providing innovative and realistic training tools, the company will help to improve the clinical skills of doctors and reduce the risk of needless errors. Medical errors are a major problem for society that come at a large cost and are the third most common cause of death in the USA, behind heart disease and cancer. Close integration with the healthcare sector and the rest of the medical device industry is vital in order to promote innovative solutions that enhance the efficiency and reduce the risks for patient- related injuries. Sustainability, social and environmental issues are a core element of Mentice’s code of conduct and its operations. Mentice has a strong focus on the continuing innovation of the products it offers and on taking simulation to new heights in order to offer the best possible solutions for customers at hospitals, clinics, universities and in research groups and the medical device industry. The company has clear ambitions and principles to take economic, social and environmental responsibility.
VISION
Mentice’s vision is to make medical simulation so realistic, effective and easy to use that Mentice’s simulators will be routinely used by physicians as a natural part of their quest for excellence.
MISSION
Mentice’s mission is to continuously innovate and develop products that make the simulation experience go beyond realism and offer the most effective and stimulating solutions. Mentice also works to closely engage with medical societies, communities and industries to help create the best possible training environment.